Hejing Biotech announced that the SGT003 injection independently developed by the holding subsidiary Shunjing Pharmaceutical is undergoing phase I/IIa clinical study, and recently completed the enrollment and administration of the first test subjects.

Hejing Biotech announced that the SGT003 injection independently developed by the holding subsidiary Shunjing Pharmaceutical is undergoing phase I/IIa clinical study, and recently completed the enrollment and administration of the first test subjects.